ANDA 217767, held by Alembic. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 217767 (Venlafaxine Hydrochloride), held by Alembic, was first approved by FDA on Jun 6, 2024, with 0 approved supplements and 0 published complete response letters.
Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2024 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters